Peregrine Pharmaceuticals  

(Public, NASDAQ:PPHM)   Watch this stock  
Find more results for PPHM
1.42
-0.04 (-2.74%)
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.40 - 1.46
52 week 1.26 - 3.18
Open 1.45
Vol / Avg. 1.42M/743,835.00
Mkt cap 258.56M
P/E     -
Div/yield     -
EPS -0.27
Shares 182.08M
Beta 1.35
Inst. own 16%
Mar 5, 2015
Q3 2015 Peregrine Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 10, 2014
Q2 2015 Peregrine Pharmaceuticals Inc Earnings Call - Webcast
Dec 10, 2014
Q2 2015 Peregrine Pharmaceuticals Inc Earnings Release
Nov 5, 2014
Peregrine Pharmaceuticals Inc at EBD Group BIO-Europe Conference
Oct 16, 2014
Peregrine Pharmaceuticals Inc Annual Shareholders Meeting - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Oct '14) 2014
Net profit margin -192.06% -157.86%
Operating margin -192.65% -159.39%
EBITD margin - -154.99%
Return on average assets -57.42% -52.16%
Return on average equity -84.70% -78.21%
Employees 180 -
CDP Score - -

Address

14282 Franklin Ave
TUSTIN, CA 92780
United States - Map
+1-714-5086000 (Phone)
+1-714-8385817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Company�s therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.

Officers and directors

Carlton M. Johnson Jr. Independent Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Steven W. King President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul J. Lytle Chief Financial Officer
Age: 46
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark R. Ziebell Vice President, General Counsel, Corporate Secretary
Age: 50
Bio & Compensation  - Reuters
Shelley P.M. Fussey Ph.D. Vice President - Intellectual Property
Age: 48
Bio & Compensation  - Reuters
Joseph S. Shan Vice President - Clinical & Regulatory Affairs
Age: 41
Bio & Compensation  - Reuters
David H. Pohl Independent Director
Age: 77
Bio & Compensation  - Reuters
Eric S. Swartz Independent Director
Age: 58
Bio & Compensation  - Reuters